Affinivax’s $226M Series C Financing

Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP advised Affinivax on the deal.

Affinivax, a clinical stage biopharmaceutical company, announced its $226 million Series C financing co-led by Rock Springs Capital and Foresite Capital.

The Gunderson deal team was led by Tim Ehrlich (Picture) and included Jeff Vetter, Jay Hachigian, Keith Scherer, Erik Thompson, Beatrice Igne-Bianchi, Gabriella Stearns, John Maciejewski, and Camil Miki Zaganjor.

Involved fees earner: Timothy Ehrlich – Gunderson Dettmer; Jay Hachigian – Gunderson Dettmer; Beatrice Igne-Bianchi – Gunderson Dettmer; John Maciejewski – Gunderson Dettmer; Keith Scherer – Gunderson Dettmer; Gabriella Stearns – Gunderson Dettmer; Jeffrey Vetter – Gunderson Dettmer;

Law Firms: Gunderson Dettmer;

Clients: Affinivax;


Author: Ambrogio Visconti